NRX Pharmaceuticals is focused on developing innovative treatments for life-threatening conditions such as severe bipolar depression and PTSD. Their lead candidate, NRX-101, is notable for being the first oral medication undergoing FDA trials specifically for suicidal bipolar depression. This investigational drug employs a dual-mechanism of action that targets both the NMDA and 5-HT2a receptors in the brain, which are crucial for regulating thought processes and emotional responses. The company’s research is rooted in the groundbreaking work of Professor Daniel Javitt, who identified the NMDA receptor's significant role in managing depression and suicidal ideation. NRX-101 has received multiple designations from the FDA, including breakthrough therapy designation, highlighting its potential to address a critical unmet need in mental health treatment.

In addition to its focus on bipolar depression, NRX Pharmaceuticals is also exploring the use of NRX-101 in treating complicated urinary tract infections, where it has shown effectiveness against resistant pathogens. The company is committed to advancing its NMDA-modulating therapies through ongoing clinical trials, with promising results from previous studies leading to FDA recognition. Their approach aims to provide non-addictive, non-sedating alternatives for patients suffering from chronic pain and mental health disorders, addressing the urgent need for effective treatments in these areas.

United States

We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. We apply our unique clinical and scientific expertise, partnered with leading medical experts, to develop known molecules for medical conditions with no indicated therapies. NRx believes in a world where scientific advancement makes untreatable diseases treatable. We are committed to bringing new treatments and hope for people with chronic medical conditions so they may live full lives.

Pathological Conditions

Psychological Diseases

NRX Pharmaceuticals

Bipolar depression

Treatment Resistant Depression

NRX-101

Suicidal Depression

<p class="font_8">fixed-dose combination oral capsule composed of D-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation or Behavior (ASIB) in adults with Bipolar Depression following initial stabilization with ketamine.</p>

NRX-100 (preservative-free IV ketamine)

Post-traumatic stress disorder

NRX-101 

Chronic pain

Acute Suicidal Ideation and Behavior

HTX-100 (IV ketamine)

COVID-19

BRILIFE

<p class="font_8">ZYESAMI (aviptadil) is a synthetic form of Vasoactive Intestinal Polypeptide (VIP) VIP binds specifically to the alveolar type II cell (ATII) in the air sac (alveolus) of the lung, where it has been shown have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, VIP stimulates ATII cells to make the surfactant that must coat the lining of the lungs in order for them to exchange oxygen with the blood.</p>

NRX Pharmaceuticals

Company Details